{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:18:00Z","timestamp":1758845880475,"version":"3.44.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1053\/j.seminoncol.2010.06.009","type":"journal-article","created":{"date-parts":[[2010,8,3]],"date-time":"2010-08-03T06:45:34Z","timestamp":1280817934000},"page":"S20-S29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S1","title":["Therapeutic Options in the Management of Myeloma Bone Disease"],"prefix":"10.1053","volume":"37","author":[{"given":"James R.","family":"Berenson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2010.06.009_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.1440","article-title":"Estimating the world cancer burden: Globocan 2000","volume":"94","author":"Parkin","year":"2001","journal-title":"Int J Cancer"},{"year":"2009","series-title":"Cancer Facts & Figures 2009","author":"Jemal","key":"10.1053\/j.seminoncol.2010.06.009_bib2"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib4","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib6","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V80.3.733.733","article-title":"C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system","volume":"80","author":"Bataille","year":"1992","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib9","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","article-title":"Myeloma bone disease: pathophysiology and management","volume":"16","author":"Terpos","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1053\/j.seminhematol.2009.01.005","article-title":"Management of complications in multiple myeloma","volume":"46","author":"Terpos","year":"2009","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib12","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1600-0609.2008.01065.x","article-title":"Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma","volume":"80","author":"Kaiser","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/blood-2008-01-132134","article-title":"Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma","volume":"112","author":"Qiang","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib14","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib15","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1210\/en.2007-0270","article-title":"Targeting the Wnt\/beta-catenin pathway to regulate bone formation in the adult skeleton","volume":"148","author":"Baron","year":"2007","journal-title":"Endocrinology"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood-2008-03-145169","article-title":"The role of Dickkopf-1 in bone development, homeostasis, and disease","volume":"113","author":"Pinzone","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-6196(25)00115-6","article-title":"Multiple myeloma: review of 869 cases","volume":"50","author":"Kyle","year":"1975","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib18","first-page":"300","article-title":"Myeloma and bone disease: \u201cthe dangerous tango\u201d","volume":"4","author":"Epstein","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib19","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib20","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib21","doi-asserted-by":"crossref","unstructured":"Terpos E, Cook R, Coleman R, Lipton A, Berenson JR. Predictors for skeletal-related events in patients with advanced multiple myeloma. Paper presented at: 49th American Society of Hematology Annual Meeting; 2007 December 8; Atlanta, GA.","DOI":"10.1182\/blood.V110.11.1482.1482"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib22","doi-asserted-by":"crossref","unstructured":"Berenson J, Cook R, Lipton A, Coleman R, Terpos E. Increased levels of urinary N-telopeptide of type I collagen correlate with reduced survival in patients with advanced multiple myeloma. Paper presented at: 49th American Society of Hematology Annual Meeting; 2007 December 8; Atlanta, GA.","DOI":"10.1182\/blood.V110.11.1499.1499"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1634\/theoncologist.9-6-687","article-title":"Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy","volume":"9","author":"Vogel","year":"2004","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib24","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2165\/00003495-200161090-00003","article-title":"The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma","volume":"61","author":"McCloskey","year":"2001","journal-title":"Drugs"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1586\/14737167.4.5.565","article-title":"Costs of multiple myeloma and associated skeletal-related events in The Netherlands","volume":"4","author":"Groot","year":"2004","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib26","first-page":"895","article-title":"Therapy of metastatic bone pain","volume":"42","author":"Serafini","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0936-6555(05)80091-3","article-title":"Double hemibody irradiation (DHBI) in the management of relapsed and primary chemoresistant multiple myeloma","volume":"5","author":"McSweeney","year":"1993","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib28","doi-asserted-by":"crossref","first-page":"6279s","DOI":"10.1158\/1078-0432.CCR-06-0681","article-title":"Treatment for myeloma bone disease","volume":"12","author":"Yeh","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib29","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1078-0432.CCR-08-1261","article-title":"A phase I study of samarium lexidronam\/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma","volume":"15","author":"Berenson","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12178-008-9042-3","article-title":"Treatment of bone tumours by radiofrequency thermal ablation","volume":"2","author":"Santiago","year":"2009","journal-title":"Curr Rev Musculoskelet Med"},{"issue":"2p","key":"10.1053\/j.seminoncol.2010.06.009_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/000164702760300302","article-title":"Surgical treatment for pathologic fracture","volume":"72","author":"Wedin","year":"2001","journal-title":"Acta Orthop Scand Suppl"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib32","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1614::AID-CNCR12>3.0.CO;2-2","article-title":"Orthopedic surgical management of skeletal complications of malignancy","volume":"80","author":"Harrington","year":"1997","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib33","first-page":"1897","article-title":"Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: technical aspects","volume":"18","author":"Jensen","year":"1997","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib34","first-page":"200","article-title":"Kyphoplasty: an assessment of a new technology","volume":"28","author":"Cloft","year":"2007","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib35","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3174\/ajnr.A0918","article-title":"Vertebroplasty in multiple myeloma: outcomes in a large patient series","volume":"29","author":"McDonald","year":"2008","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.blo.0000131642.96984.74","article-title":"Kyphoplasty enhances function and structural alignment in multiple myeloma","volume":"462","author":"Lane","year":"2004","journal-title":"Clin Orthop Relat Res"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib37","unstructured":"Berenson JR, Pflugmacher R, Jarzem P, et al. Final results of the first randomized trial comparing balloon kyphoplasty (BKP) to non-surgical management among cancer patients with vertebral compression fractures: marked improvement in back function, quality of life and pain in the BKP arm. Paper presented at: 48th American Society of Hematology Annual Meeting and Exposition. 2006 December 9; Orlando, FL."},{"key":"10.1053\/j.seminoncol.2010.06.009_bib38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib39","unstructured":"Henk HJ, Kaura S, Perez JS, Becker L. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events in patients with multiple myeloma. Paper presented at: 51st American Society of Hematology Annual Meeting and Exposition; 2009 December 5; New Orleans, LA."},{"key":"10.1053\/j.seminoncol.2010.06.009_bib40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.coc.0000138966.66780.3e","article-title":"Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma","volume":"28","author":"Reed","year":"2005","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib41","first-page":"487s","article-title":"A retrospective database analysis to assess the impact of zoledronic acid (ZOL) on skeletal-related events (SREs) in solid tumor cancer and multiple myeloma (MM) patients (pts) [abstract]","volume":"27","author":"Thayer","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2165\/00002512-199914040-00001","article-title":"Bisphosphonate treatment of lytic bone metastases","volume":"14","author":"Lipton","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib43","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib44","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1365-2141.1994.tb06730.x","article-title":"Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma","volume":"87","author":"Laakso","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib46","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib47","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2141.1998.00695.x","article-title":"Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial","volume":"101","author":"Brincker","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib48","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib49","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib50","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib51","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib52","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib53","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib54","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003188","article-title":"Bisphosphonates in multiple myeloma","author":"Djulbegovic","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib56","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02698044","article-title":"Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma","volume":"24","author":"Aviles","year":"2007","journal-title":"Med Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib57","unstructured":"Berenson J, Dimopoulos M, Chen Y-M. Improved survival in patients with multiple myeloma and high BALP levels treated with zoledronic acid compared with pamidronate: univariate and multivariate models of hazard ratios. Paper presented at: 48th American Society of Hematology Annual Meeting. 2006 December 9; Orlando, FL."},{"key":"10.1053\/j.seminoncol.2010.06.009_bib58","doi-asserted-by":"crossref","unstructured":"Henry D, von Moos R, Vadhan-Raj S, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Paper presented at: ECCO 15 - 34th ESMO Multidisciplinary Congress. 2009 September 20; Berlin, Germany.","DOI":"10.1016\/S1359-6349(09)72055-5"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib59","doi-asserted-by":"crossref","unstructured":"Morgan G, Davies F, Gregory W, et al. Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): results of the Medical Research Council (MRC) Myeloma IX study. Presented at: 46th Annual Meeting of the American Society of Clinical Oncology; 2010 June 4; Orlando, FL.","DOI":"10.1200\/jco.2010.28.15_suppl.8021"},{"article-title":"NCCN National Comprehensive Cancer Network Guidelines in Oncology","year":"2010","series-title":"Multiple Myeloma","key":"10.1053\/j.seminoncol.2010.06.009_bib61"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib62","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib63","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients\u2014May 2006","volume":"62","author":"Weitzman","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib64","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib65","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1200\/JCO.2008.16.9300","article-title":"Natural history of osteonecrosis of the jaw in patients with multiple myeloma","volume":"26","author":"Badros","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib66","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/10428190802483778","article-title":"Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates","volume":"49","author":"Montefusco","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib67","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/annonc\/mdn630","article-title":"Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome","volume":"20","author":"Van den Wyngaert","year":"2009","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"10.1053\/j.seminoncol.2010.06.009_bib68","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/BF02553287","article-title":"Incidence and pathophysiology of hypercalcemia","volume":"46","author":"Mundy","year":"1990","journal-title":"Calcif Tissue Int"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib69","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.06.009_bib70","first-page":"539","article-title":"Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate","volume":"11","author":"Pecherstorfer","year":"2003","journal-title":"Support Care Cancer"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775410000886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775410000886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:53:07Z","timestamp":1758804787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775410000886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":69,"alternative-id":["S0093775410000886"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2010.06.009","relation":{},"ISSN":["0093-7754"],"issn-type":[{"type":"print","value":"0093-7754"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Options in the Management of Myeloma Bone Disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2010.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}